Reports

Ideas That Generate Results

Global Parkinsons Disease Drugs Market Outlook 2022

Global Parkinsons Disease Drugs Market Outlook 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Jan, 2018| No. of Pages : 100

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 2000.00
CD-ROM Mail Delivery
US$ 2200.00
Hard Copy Mail Delivery
US$ 2200.00
Electronic Access - Multi-User License
US$ 2800.00
1. Analyst View
 
2. Research Methodology
 
3. Parkinson’s Disease: An Overview
 
4. Market Dynamics
     4.1 Drivers
           4.1.1 Increasing Funding Support & Research Grants
           4.1.2 Increasing Awareness
           4.1.3 Rising Healthcare Expenditure
           4.1.4 Increasing Life Expectancy
     4.2 Challenges
           4.2.1 Patent Expiry of Blockbuster Drugs
           4.2.2 High Cost of Treatment
           4.2.3 Side-Effects of Parkinson’s Disease Drugs
     4.3 Opportunities
           4.3.1 Collaborations with Academic Institutions for Developing Innovative Solutions
           4.3.2 Reduction in “Off” Time to Improve Patient and Economic Outcomes
           4.3.3 Growing Geriatric Population
 
5. Global Parkinson’s Disease Drugs Market Outlook 2022
 
6. Major Products in Parkinson’s Disease Market
    6.1 Duodopa/Duopa
    6.2 Azilect
    6.3 Mirapex/Mirapex ER
    6.4 Requip
    6.5 Neupro
    6.6 Rytary/Numient
    6.7 Xadago
    6.8 Nuplazid
 
7. Market Segmentation by Type of Therapy
    7.1 Levodopa Therapy
    7.2 Dopamine Agonist Therapy
    7.3 MAO-B Inhibitor Therapy
    7.4 COMT Inhibitor Therapy
    7.5 Other Therapy
 
8. Market Segmentation by Geography
    8.1 North America
    8.2 Europe
    8.3 Asia-Pacific
 
9. Trends & Developments
    9.1 Stem Cell Therapies - Revolutionizing Parkinson Treatment
    9.2 Incessant Launch of Novel Products
 
10. Mergers & Acquisitions
 
11. Drugs Pipeline of Parkinson’s Disease
 
12. Company Profiles
      12.1 Abbvie Inc.
      12.2 Newron Pharmaceuticals SpA
      12.3 Acadia Pharmaceuticals Inc.
      12.4 Boehringer Ingelheim International GmbH
      12.5 Teva Pharmaceutical Industries Limited
      12.6 GlaxoSmithKline plc
      12.7 UCB S.A.
      12.8 Novartis AG
      12.9 Impax Laboratories, Inc.
      12.10 Valeant Pharmaceuticals International, Inc.
      12.11 Merck & Co., Inc.
      12.12 Mylan N.V.
      12.13 F. Hoffmann-La Roche Ltd.
      12.14 US WorldMeds, LLC
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.